GLP-1 Providers in Indiana (2026)

351 of the 444 sellers that publish a state list include Indiana, the 27th-most of the 50 states and DC. 226 of them ship to all 50 states, and 3 serve 15 states or fewer. Across the 244 with a regular monthly price, the middle figure is $169/mo.

Indiana Medicaid does not pay for GLP-1 drugs prescribed only for weight loss. GLP-1s prescribed for type 2 diabetes are covered, with prior authorization.

Sellers and prices are broken out by drug on the semaglutide in Indiana and tirzepatide in Indiana pages.

Who Ships GLP-1s to Indiana

1. WellMedRx $49/mo
2. Collective $59/mo
3. RxPepsDirect $64/mo

Lowest regular prices for Indiana: WellMedRx at $49/mo, Collective at $59/mo and RxPepsDirect at $64/mo.

Smaller-footprint sellers that include Indiana: Gaya Wellness (5 states), LIV by WellNow (5 states) and SynergenX Health (10 states).

11 sellers that list 30 or more states leave Indiana off, among them EdgeRx, Brello Health, Bloom MD, NP2GO and Welm Health.

Seller counts next door: Illinois 368, Kentucky 350, Michigan 363 and Ohio 357.

Browse by medication

Indiana Medicaid and GLP-1 Coverage

Indiana Medicaid does not pay for GLP-1 drugs prescribed only for weight loss. GLP-1s prescribed for type 2 diabetes are covered, with prior authorization.

• Wegovy to cut heart attack and stroke risk: covered with prior authorization (Age 45+, BMI 27+, a past heart attack or stroke, or symptomatic peripheral artery disease, on beta-blocker or RAS inhibitor plus lipid-lowering therapy (or justification), no diabetes of either type).
• Wegovy for the liver disease MASH: covered with prior authorization (fibrosis stage F2, F3).
• Zepbound for obstructive sleep apnea: covered with prior authorization (an AHI of at least 15; a BMI of at least 30; no CPAP trial required).
• Weight-loss GLP-1s for adolescents from age 21: covered with prior authorization.

In 2025, Indiana Medicaid paid for at least 190,013 GLP-1 prescriptions, including at least 135,539 for Ozempic, at least 3,297 for Wegovy, at least 13,709 for Mounjaro and at least 5,452 for Zepbound, about $204.6 million before manufacturer rebates. Drugs labeled for weight loss made up 5% of that spending.

Medicaid rules checked November 2026. Prescription counts: CMS State Drug Utilization Data. Check your eligibility

Specialist Clinics and Obesity in Indiana

Indiana has 523 practices in the federal provider registry that list obesity medicine, endocrinology or bariatric care, 7.55 per 100,000 residents (36th of 51). By specialty: 265 bariatric, 250 endocrinology and 19 obesity medicine. About 38.4% of adults here had obesity in 2024 (CDC), the 6th-highest rate of the 50 states and DC. Measured against the median state, Indiana has 1.26 times as much adult obesity per specialist practice.

Largest Cities in Indiana

Frequently Asked Questions